Acceleron (XLRN) option implied volatility flat into Phase III Believe results

Acceleron Pharma (NASDAQ: XLRN) July call option implied volatility is at 62, August is at 56; compared to its 52-week range of 37 to 152 into announcing with its partner Celgene (CELG) positive Phase III Believe results for luspatercept in transfusion dependent beta thalassemia.

You May Also Be Interested In

• Senate votes to halt Iran war unless Trump gets approval from Congress
• Walmart to pay $1.4 billion for Vibe.co acquisition - WSJ
• SPS Commerce (SPSC) 400 contracts of July 60 calls trade